Literature DB >> 34965942

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.

Toni K Choueiri1, Laurence Albiges2, Michael B Atkins3, Ziad Bakouny1, Gennady Bratslavsky4, David A Braun1, Naomi B Haas5, John B A G Haanen6, A Ari Hakimi7, Michael A S Jewett8, Eric Jonasch9, William G Kaelin1, Payal Kapur10, Chris Labaki1, Bryan Lewis11, David F McDermott12, Sumanta K Pal13, Kevin Pels1, Susan Poteat11, Thomas Powles14, W Kimryn Rathmell15, Brian I Rini15, Sabina Signoretti16, Nizar M Tannir9, Robert G Uzzo17, Hans J Hammers18.   

Abstract

The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2022        PMID： 34965942      PMCID： PMC9223120          DOI： 10.1158/1078-0432.CCR-21-3238

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  96 in total

1.  Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.

Authors:  Toni K Choueiri; Michael B Atkins; Ziad Bakouny; Maria I Carlo; Charles G Drake; Eric Jonasch; Payal Kapur; Bryan Lewis; W Marston Linehan; Michael J Mitchell; Sumanta K Pal; Kevin Pels; Susan Poteat; W Kimryn Rathmell; Brian I Rini; Sabina Signoretti; Nizar Tannir; Robert Uzzo; Christopher G Wood; Hans J Hammers
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

2.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

3.  Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Authors:  Steffen Durinck; Eric W Stawiski; Andrea Pavía-Jiménez; Zora Modrusan; Payal Kapur; Bijay S Jaiswal; Na Zhang; Vanina Toffessi-Tcheuyap; Thong T Nguyen; Kanika Bajaj Pahuja; Ying-Jiun Chen; Sadia Saleem; Subhra Chaudhuri; Sherry Heldens; Marlena Jackson; Samuel Peña-Llopis; Joseph Guillory; Karen Toy; Connie Ha; Corissa J Harris; Eboni Holloman; Haley M Hill; Jeremy Stinson; Celina Sanchez Rivers; Vasantharajan Janakiraman; Weiru Wang; Lisa N Kinch; Nick V Grishin; Peter M Haverty; Bernard Chow; Julian S Gehring; Jens Reeder; Gregoire Pau; Thomas D Wu; Vitaly Margulis; Yair Lotan; Arthur Sagalowsky; Ivan Pedrosa; Frederic J de Sauvage; James Brugarolas; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2014-11-17       Impact factor: 38.330

4.  BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.

Authors:  Nicolas Epaillard; Audrey Simonaggio; Reza Elaidi; Fouzia Azzouz; Elena Braychenko; Constance Thibault; Cheng-Ming Sun; Marco Moreira; Stéphane Oudard; Yann-Alexandre Vano
Journal:  Bull Cancer       Date:  2020-06       Impact factor: 1.276

5.  Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.

Authors:  Yoshiro Nakahara; Takaji Matsutani; Yuka Igarashi; Norikazu Matsuo; Hidetomo Himuro; Haruhiro Saito; Kouzo Yamada; Kenta Murotani; Tomoaki Hoshino; Koichi Azuma; Tetsuro Sasada
Journal:  Cancer Immunol Immunother       Date:  2021-03-09       Impact factor: 6.968

6.  Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors.

Authors:  Patrick A Ott; Catherine J Wu
Journal:  Cancer Discov       Date:  2019-03-12       Impact factor: 39.397

7.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

8.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.

Authors:  Adam C Palmer; Peter K Sorger
Journal:  Cell       Date:  2017-12-14       Impact factor: 41.582

9.  Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.

Authors:  Toni K Choueiri; Todd M Bauer; Kyriakos P Papadopoulos; Elizabeth R Plimack; Jaime R Merchan; David F McDermott; M Dror Michaelson; Leonard J Appleman; Sanjay Thamake; Rodolfo F Perini; Naseem J Zojwalla; Eric Jonasch
Journal:  Nat Med       Date:  2021-04-22       Impact factor: 87.241

10.  PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.

Authors:  Xian-De Liu; Wen Kong; Christine B Peterson; Daniel J McGrail; Anh Hoang; Xuesong Zhang; Truong Lam; Patrick G Pilie; Haifeng Zhu; Kathryn E Beckermann; Scott M Haake; Sevinj Isgandrova; Margarita Martinez-Moczygemba; Nidhi Sahni; Nizar M Tannir; Shiaw-Yih Lin; W Kimryn Rathmell; Eric Jonasch
Journal:  Nat Commun       Date:  2020-05-01       Impact factor: 14.919
View more
  3 in total

1.  Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Thomas Denize; Yue Hou; Jean-Christophe Pignon; Emily Walton; Destiny J West; Gordon J Freeman; David A Braun; Catherine J Wu; Saurabh Gupta; Robert J Motzer; Michael B Atkins; David McDermott; Toni K Choueiri; Sachet A Shukla; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

2.  Iron accumulation typifies renal cell carcinoma tumorigenesis but abates with pathological progression, sarcomatoid dedifferentiation, and metastasis.

Authors:  Christopher J Greene; Kristopher Attwood; Nitika J Sharma; Benjamin Balderman; Rongia Deng; Jason B Muhitch; Gary J Smith; Kenneth W Gross; Bo Xu; Eric C Kauffman
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

3.  Comprehensive analysis of FRAS1/FREM family as potential biomarkers and therapeutic targets in renal clear cell carcinoma.

Authors:  Ganggang Wang; Zheng Wang; Haiquan Lu; Zhiqun Zhao; Liqiang Guo; Feng Kong; Aizhen Wang; Shengtian Zhao
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.